Joly Véronique, Ferré Valentine M, Le Hingrat Quentin, Peytavin Gilles, Cresta Mélanie, Charpentier Charlotte, Digumber Marc, Damond Florence, Yazdanpanah Yazdan, Matheron Sophie, Descamps Diane, Ghosn Jade
IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP Laboratoire de Virologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
Clin Infect Dis. 2025 Mar 17;80(3):618-620. doi: 10.1093/cid/ciae447.
This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.
这项回顾性研究评估了比克替拉韦（BIC）/恩曲他滨（FTC）/替诺福韦艾拉酚胺（TAF）在24例2型人类免疫缺陷病毒（HIV-2，HIV-2感染者）中的疗效，其中5例初治患者，19例经治患者。中位随访37.5个月后，所有HIV-2感染者的血浆病毒载量均<40拷贝/mL。CD4细胞计数中位数从580显著增加至625个细胞/mm³，表明BIC/FTC/TAF治疗HIV-2感染有效。
